Opening Remarks
Opening Remarks 
Dr. Wen-Chien Chou
MPN: What's New?
MPN Updates and the Evolution of the Disease  
Dr. Ruben Mesa
Clinical Relevance of Mutation Allele Burden in MPN  
Dr. Hsin-An Hou
A Paradigm Shift in The Diagnosis and Treatment of MPNs, Sooner Better than Later?  
Dr. Hans K Hasselbalch
Interferon Treatment in PV: Revolution

Six-year Results of the PROUD/CONTI-PV Study

Dr. Jean-Jacques Kiladjian

Efficacy and Safety of Ropeginterferon Alfa-2b Treatment in Japanese Patients with PV

Dr. Keita Kirito

Molecular Response of Ropeginterferon Alfa-2b in Korea Patients with PV

Dr. Sung-Eun Lee

Clinical Diagnosis and Characteristics of MPN
Polycythemia Vera 2023. Can We Improve Outcomes?
Dr. Josef Prchal
Clinical Characteristics of Japanese Patients with PV/ET
Dr. Katsuto Takenaka 
Clinicophenotype of Essential Thrombocythemia in Asian Patients
Dr. Chin-Hin Ng 
Unmet Needs and Advances in MPN

Intervention in Prefibrotic and Early Overt Myelofibrosis

Dr. Abdulraheem Yacoub 

Ropeginterferon Alfa-2b in Early Myelofibrosis

Dr. Harry Gill 

Long-Acting Interferon and Ropeginterferon:
Lessons from Finite-Period Therapy of Chronic Viral Hepatitis to Long-term Therapy for MPN

Dr. Pei-Jer Chen

Panel Discussion

Panel Discussion  

Dr. Jean-Jacques Kiladjian & Dr. Hwei-Fang Tien

Closing Remaks

Closing Remarks 

Dr. Wen-Chien Chou